AI Analyst Summary
AbbVie's bull thesis centers on the rapid ramp of Skyrizi and Rinvoq, which together are on track to exceed peak Humira revenues and have driven 10.2% top-line growth even as biosimilar headwinds persist. A strikingly low PEG of 0.41 and a forward P/E of 15.3x suggest the market is underpricing durable earnings power, while a 290%+ YoY EPS surge — aided by base effects — signals a meaningful inflection point. The key risk is that Skyrizi/Rinvoq growth stalls or faces unexpected competitive or regulatory pressure before the pipeline matures.
Fundamentals
Pe
Trailing P/E 70.5x / Forward P/E 15.3x · 3.0/5
The trailing P/E of 70.5x looks elevated, but this is heavily distorted by prior-year charges; the forward P/E of 15.3x is materially below the sector median for a large-cap biopharma, suggesting genuine value on a forward basis. Neutral-to-constructive overall.
Peg
PEG 0.41 · 5.0/5
A PEG of 0.41 is well below 1.0, indicating AbbVie is significantly undervalued relative to its near-term earnings growth trajectory. This is a strong positive signal, especially given the durability of its immunology and neuroscience franchises.
Analyst Rating
Buy consensus (1.7) · 4.0/5
Consensus rating of 1.7 on the inverted scale maps to a solid Buy, backed by 25 Buy ratings vs. only 1 Sell out of 29 analysts. Broad bullish conviction with limited dissent is a constructive signal.
Earnings Trend
EPS Growth +290.4% YoY; Revenue Growth +10.2% YoY · 4.0/5
YoY EPS growth of 290.4% is exceptional, though it is partly base-effect driven from prior-year impairments. Revenue growth of 10.2% reflects genuine top-line momentum from Skyrizi and Rinvoq offsetting Humira biosimilar erosion. Growth is strong but sustainability of this rate limits the score to 4.
Price Target Beat
3 of 4 quarters beat (last 4 quarters; 8-quarter history insufficient) · 3.0/5
With only 4 quarters of beat data available, the score is capped at 3 per guidelines for insufficient history, despite a solid 3-of-4 beat rate. Execution has been consistent recently, which is encouraging.
Management
Consistent execution with strong pipeline capital allocation · 4.0/5
Management has demonstrated disciplined capital allocation — navigating the Humira biosimilar cliff via accelerated investment in Skyrizi and Rinvoq — alongside a strong dividend track record and strategic M&A (Cerevel, ImmunoGen). Analyst confidence is high, supporting a 4 score.
● See the full picture
Get today's top-scored picks, ranked for you.
Compass screens thousands of stocks every morning and hands you a short list of high-conviction picks — scored, explained, and re-ranked to your risk profile.
Start free for 3 days →
No credit card. Then $9/month. Cancel anytime.
How Compass scores stocks
Compass pre-filters thousands of U.S. equities by fundamentals, then an AI analyst scores each finalist 1–5 across six measures — spanning valuation, growth, analyst sentiment, and management quality — into one composite score, refreshed every market morning. Browse all covered stocks →
Not financial advice.
Compass is an analytical tool, not a registered investment adviser or broker-dealer.
Scores and recommendations are generated by AI, may be inaccurate or out of date, and are
not investment, financial, legal, or tax advice. Investing involves risk, including loss of
principal. Do your own research and consult a licensed financial professional.
About Compass.